
Novo Nordisk Shares Drop Amid Leadership Change and Profit Warnings
Novo Nordisk's stock fell 22% after lowering its 2025 sales and profit growth forecasts and appointing Maziar Mike Doustdar as the new CEO, amid increased competition for its diabetes and obesity drugs.
